Home Healthcare Biotechnology Biomarker Discovery Outsourcing Service Market

Biomarker Discovery Outsourcing Service Market Size, Share & Trends Analysis Report By Biomarker Type (Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers, Surrogate Endpoints), By Therapeutic Area (Oncology, Neurology, Cardiology, Autoimmune Diseases, Other Therapeutic Area), By Discovery Phase (Biomarker Identification, Biomarker Validation, Biomarker Profiling, Biomarker Panel Development, Biomarker Selection), By End Use (Pharmaceutical Companies, Biotechnology Companies, CDMOs) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: October 21, 2026 | Author: Debashree Bora | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Biomarker Discovery Outsourcing Service Market, By Biomarker Type 2025-2034 (USD MILLION/ Units)
    1. Predictive Biomarkers
    2. Prognostic Biomarkers
    3. Safety Biomarkers
    4. Surrogate Endpoints
  2. Biomarker Discovery Outsourcing Service Market, By Therapeutic Area 2025-2034 (USD MILLION/ Units)
    1. Oncology
    2. Neurology
    3. Cardiology
    4. Autoimmune Diseases
    5. Other Therapeutic Area
  3. Biomarker Discovery Outsourcing Service Market, By Discovery Phase 2025-2034 (USD MILLION/ Units)
    1. Biomarker Identification
    2. Biomarker Validation
    3. Biomarker Profiling
    4. Biomarker Panel Development
    5. Biomarker Selection
  4. Biomarker Discovery Outsourcing Service Market, By End Use 2025-2034 (USD MILLION/ Units)
    1. Pharmaceutical Companies
    2. Biotechnology Companies
    3. CDMOs
  5. Regional Biomarker Discovery Outsourcing Service Market
    1. North America
      1. North America Biomarker Discovery Outsourcing Service Market By Biomarker Type 2025-2034 (USD MILLION/ Units)
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
      2. North America Biomarker Discovery Outsourcing Service Market By Therapeutic Area 2025-2034 (USD MILLION/ Units)
        1. Oncology
        2. Neurology
        3. Cardiology
        4. Autoimmune Diseases
        5. Other Therapeutic Area
      3. North America Biomarker Discovery Outsourcing Service Market By Discovery Phase 2025-2034 (USD MILLION/ Units)
        1. Biomarker Identification
        2. Biomarker Validation
        3. Biomarker Profiling
        4. Biomarker Panel Development
        5. Biomarker Selection
      4. North America Biomarker Discovery Outsourcing Service Market By End Use 2025-2034 (USD MILLION/ Units)
        1. Pharmaceutical Companies
        2. Biotechnology Companies
        3. CDMOs
      5. U.S.
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
      6. Canada
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
    2. Europe
      1. Europe Biomarker Discovery Outsourcing Service Market By Biomarker Type 2025-2034 (USD MILLION/ Units)
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
      2. Europe Biomarker Discovery Outsourcing Service Market By Therapeutic Area 2025-2034 (USD MILLION/ Units)
        1. Oncology
        2. Neurology
        3. Cardiology
        4. Autoimmune Diseases
        5. Other Therapeutic Area
      3. Europe Biomarker Discovery Outsourcing Service Market By Discovery Phase 2025-2034 (USD MILLION/ Units)
        1. Biomarker Identification
        2. Biomarker Validation
        3. Biomarker Profiling
        4. Biomarker Panel Development
        5. Biomarker Selection
      4. Europe Biomarker Discovery Outsourcing Service Market By End Use 2025-2034 (USD MILLION/ Units)
        1. Pharmaceutical Companies
        2. Biotechnology Companies
        3. CDMOs
      5. U.K.
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
      6. Germany
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
      7. France
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
      8. Spain
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
      9. Italy
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
      10. Russia
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
      11. Nordic
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
      12. Benelux
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
      13. Rest of Europe
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
    3. APAC
      1. APAC Biomarker Discovery Outsourcing Service Market By Biomarker Type 2025-2034 (USD MILLION/ Units)
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
      2. APAC Biomarker Discovery Outsourcing Service Market By Therapeutic Area 2025-2034 (USD MILLION/ Units)
        1. Oncology
        2. Neurology
        3. Cardiology
        4. Autoimmune Diseases
        5. Other Therapeutic Area
      3. APAC Biomarker Discovery Outsourcing Service Market By Discovery Phase 2025-2034 (USD MILLION/ Units)
        1. Biomarker Identification
        2. Biomarker Validation
        3. Biomarker Profiling
        4. Biomarker Panel Development
        5. Biomarker Selection
      4. APAC Biomarker Discovery Outsourcing Service Market By End Use 2025-2034 (USD MILLION/ Units)
        1. Pharmaceutical Companies
        2. Biotechnology Companies
        3. CDMOs
      5. China
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
      6. Korea
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
      7. Japan
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
      8. India
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
      9. Australia
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
      10. Taiwan
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
      11. South East Asia
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
      12. Rest of Asia-Pacific
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
    4. Middle East and Africa
      1. Middle East and Africa Biomarker Discovery Outsourcing Service Market By Biomarker Type 2025-2034 (USD MILLION/ Units)
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
      2. Middle East and Africa Biomarker Discovery Outsourcing Service Market By Therapeutic Area 2025-2034 (USD MILLION/ Units)
        1. Oncology
        2. Neurology
        3. Cardiology
        4. Autoimmune Diseases
        5. Other Therapeutic Area
      3. Middle East and Africa Biomarker Discovery Outsourcing Service Market By Discovery Phase 2025-2034 (USD MILLION/ Units)
        1. Biomarker Identification
        2. Biomarker Validation
        3. Biomarker Profiling
        4. Biomarker Panel Development
        5. Biomarker Selection
      4. Middle East and Africa Biomarker Discovery Outsourcing Service Market By End Use 2025-2034 (USD MILLION/ Units)
        1. Pharmaceutical Companies
        2. Biotechnology Companies
        3. CDMOs
      5. UAE
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
      6. Turkey
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
      7. Saudi Arabia
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
      8. South Africa
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
      9. Egypt
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
      10. Nigeria
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
      11. Rest of MEA
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
    5. LATAM
      1. LATAM Biomarker Discovery Outsourcing Service Market By Biomarker Type 2025-2034 (USD MILLION/ Units)
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
      2. LATAM Biomarker Discovery Outsourcing Service Market By Therapeutic Area 2025-2034 (USD MILLION/ Units)
        1. Oncology
        2. Neurology
        3. Cardiology
        4. Autoimmune Diseases
        5. Other Therapeutic Area
      3. LATAM Biomarker Discovery Outsourcing Service Market By Discovery Phase 2025-2034 (USD MILLION/ Units)
        1. Biomarker Identification
        2. Biomarker Validation
        3. Biomarker Profiling
        4. Biomarker Panel Development
        5. Biomarker Selection
      4. LATAM Biomarker Discovery Outsourcing Service Market By End Use 2025-2034 (USD MILLION/ Units)
        1. Pharmaceutical Companies
        2. Biotechnology Companies
        3. CDMOs
      5. Brazil
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
      6. Mexico
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
      7. Argentina
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
      8. Chile
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
      9. Colombia
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
      10. Rest of LATAM
        1. Predictive Biomarkers
        2. Prognostic Biomarkers
        3. Safety Biomarkers
        4. Surrogate Endpoints
        5. Oncology
        6. Neurology
        7. Cardiology
        8. Autoimmune Diseases
        9. Other Therapeutic Area
        10. Biomarker Identification
        11. Biomarker Validation
        12. Biomarker Profiling
        13. Biomarker Panel Development
        14. Biomarker Selection
        15. Pharmaceutical Companies
        16. Biotechnology Companies
        17. CDMOs
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.